{
    "2020-07-21": [
        [
            {
                "time": "",
                "original_text": "新股解读|CRO赛道美如舫，泰格医药能否顶格打新？",
                "features": {
                    "keywords": [
                        "新股",
                        "CRO",
                        "赛道",
                        "泰格医药",
                        "打新"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "艾德一站通：泰格医药即将招股，或成今年亚洲规模最大的医疗IPO",
                "features": {
                    "keywords": [
                        "艾德一站通",
                        "泰格医药",
                        "招股",
                        "医疗IPO",
                        "亚洲规模"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}